With better drugs come great platform technology

We develop innovative drugs with our unique antibody-
fragment platform technology

SAFA enhances efficacy, safety and half-life

SAFA platform brings better drugs
with greater performance

SCROLL

Introducing SAFAbody™

Developing auto-immune and
oncology drugs with SAFA™ platform

SAFA(anti-Serum Albumin Fab Associated) not only enhances efficacy
and half-life but minimizes adverse effects

Our Story

TECHNOLOGY

SAFA™ is an albumin binder
with many strengths

Efficacy
Efficient in targeting toward
inflammation and tumors
Adverse effects and
immunogenicity
Human antibody designed,

low in immunogenicity and minimized in adverse effects
Expandability
To be widely applied to antibodies,
cytokines, hormones and many more
Half-life
Capable of developing long-acting
drugs using half-life period of albumin

R&D

We study to develop treatments for
auto-immune and multi-target base oncology drugs

PIPELINE

Introducing our unique
"in our own way" pipelines
  • APB-A1
  • APB-R3
Read more

TECHNOLOGY

We solve medical unmet needs
with our own albumin
platform technology
  • 독점성
  • 차별성
  • 확장성
  • 낮은 부작용
  • 반감기 증대
Read more